echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Youzhiyou Biotech completes B-2 round of financing for the clinical development of M701 and M802

    Youzhiyou Biotech completes B-2 round of financing for the clinical development of M701 and M802

    • Last Update: 2021-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Text|Pharmaceutical Mission Hills

    On September 10, Wuhan Youzhiyou Biopharmaceutical Co.


    According to the information on the official website of Youzhiyou Biology, M701 is a recombinant anti-EpCAM and CD3 human-mouse chimeric bispecific antibody product for injection.


    M802 is a recombinant anti-HER2 and CD3 humanized bispecific antibody product for injection.


    Previously, these two CD3-targeted double antibody projects have been clinically approved in China


    With the completion of the B-2 round of financing, Youzhiyou Bio obtained the B-round financing led by Tongde Investment, BGI, Sanhua Hongdao, Wuhan Biotechnology Research Institute and other institutions participated in the completion of the B round of financing, and the financing amount exceeded 250 million yuan


    Reference materials:

    [1]Youzhiyou Biotech completed the B-2 round of financing.


    [2] Yzybio official website.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.